Mark Vincent
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (NCT04335292) | Mark Vincent | 2021-01-06 |
Track Mark Vincent automatically
Every clearance here is in the API, with alerts when new ones post.